1- https://doi.org/10.1182/blood.v128.22.103.103
Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies
Translate Article 
Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies
- Abstract
- 4
- 10.1182/blood-2020-136408
- Nov 5, 2020
- Blood
Worldwide Examination of Patients with CLL Hospitalized for COVID-19
- Abstract
- 10.1182/blood.v130.suppl_1.4141.4141
- Jun 25, 2021
- Blood
Efficacy of Salvage Chemotherapy in Diffuse Large B Cell Lymphoma with Primary Treatment Failure According to Putative Cell of Origin
- Abstract
- 4
- 10.1182/blood-2019-122778
- Nov 13, 2019
- Blood
Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study
- Abstract
- 11
- 10.1182/blood-2021-154729
- Dec 4, 2021
- Blood
The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
- Abstract
- 10.1182/blood-2018-99-118159
- Nov 29, 2018
- Blood
Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings
- Abstract
- 17
- 10.1182/blood-2020-137524
- Nov 5, 2020
- Blood
Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Abstract
- 1
- 10.1182/blood-2019-122900
- Nov 13, 2019
- Blood
Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study
- Abstract
- 15
- 10.1182/blood-2020-134398
- Nov 5, 2020
- Blood
The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
- Abstract
- 4
- 10.1182/blood-2018-99-110563
- Nov 29, 2018
- Blood
The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas
- Abstract
- 10.1182/blood.v128.22.513.513
- Dec 2, 2016
- Blood
Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features
- Abstract
- 1
- 10.1182/blood-2019-124116
- Nov 13, 2019
- Blood
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
- Abstract
- 60
- 10.1182/blood-2019-129097
- Nov 13, 2019
- Blood
Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
- Abstract
- 42
- 10.1182/blood-2018-99-115252
- Nov 29, 2018
- Blood
Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel
- Abstract
- 97
- 10.1182/blood.v130.suppl_1.577.577
- Jun 25, 2021
- Blood
Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Abstract
- 5
- 10.1182/blood-2019-122573
- Nov 13, 2019
- Blood
Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Save Important notes in documents
Highlight text to save as a note, or write notes directly
You can also access these Documents in Paperpal, our AI writing tool
Powered by our AI Writing Assistant
